Hepatitis C News and Research

Latest Hepatitis C News and Research

Alios, Vertex sign worldwide license agreement to develop new hepatitis C combination medicines

Vertex Pharmaceuticals Incorporated and Alios BioPharma, Inc. today announced an exclusive worldwide licensing agreement that will add two distinct nucleotide analogues to Vertex's hepatitis C portfolio.

13 Jun 2011

MinuteClinic, OhioHealth enter affiliation to enhance high quality care services

MinuteClinic, the retail health care division of CVS Caremark, and OhioHealth, a nationally recognized not-for-profit, charitable health care organization based in Columbus, Ohio, have entered into a clinical affiliation that will enhance the high quality, affordable health care services they provide in central Ohio.

13 Jun 2011

Vertex VX-770 Phase 3 STRIVE study for cystic fibrosis demonstrates improvements in lung function

Vertex Pharmaceuticals Incorporated today announced the final results from its pivotal Phase 3 STRIVE study that evaluated VX-770, a medicine in development that targets the defective protein that causes cystic fibrosis (CF).

10 Jun 2011

Mortality from all causes higher among hepatitis C-infected patients, study finds

Although liver-related mortality among those infected with hepatitis C is well-documented, little is known about deaths in these patients that are not related to liver problems. A new study published in Clinical Infectious Diseases and now available online sought to determine mortality from all causes, including liver- and non-liver related deaths among hepatitis C patients in the general U.S. population. The analysis found mortality from all causes to be higher in these patients.

10 Jun 2011

NIAID awards Biota $2.9M grant for development of lead candidate for C. difficile

Biota Holdings Limited advises that its wholly owned subsidiary, Biota Scientific Management Pty Ltd, has been awarded a grant to fund the preclinical development of a lead candidate for the treatment of Clostridium difficile (C. difficile).

10 Jun 2011

Vertex announces interim results from VX-770 and VX-809 Phase 2 study on cystic fibrosis

Vertex Pharmaceuticals Incorporated today announced interim results from the first part of a Phase 2 study designed to evaluate multiple combination regimens of VX-770 and VX-809, Vertex's lead medicines in development that aim to treat the defective protein that causes cystic fibrosis.

9 Jun 2011

Cancer professionals urge world leaders to attend U.N. meeting on NCDs

The American Society of Clinical Oncology (ASCO) on Monday sent a letter signed by major U.S. medical societies representing about 300,000 health care professionals to the White House urging President Barack Obama to participate in the U.N. High Level Meeting on Noncommunicable Diseases that is scheduled for September, Agence France-Presse reports.

9 Jun 2011

Rockefeller, Scripps Research develop first genetically humanized mouse model for hepatitis C

Scientists at Rockefeller University and The Scripps Research Institute have developed the first genetically humanized mouse model for hepatitis C, an achievement that will enable researchers to test molecules that block entry of the hepatitis C virus into cells as well as potential vaccine candidates. The finding is reported in the June 9 issue of the journal Nature.

9 Jun 2011

Hepatitis C virus (HCV)-associated liver disease after liver transplantation

Hepatitis C virus (HCV)-associated liver disease continues to be the most common indication for liver transplantation (LT) in the United States accounting for nearly 50% of all liver transplants. Recurrence is universal in patients viremic at the time of transplantation with histological hepatitis developing in the majority of patients. Although the natural history of recurrent HCV is difficult to predict, it is widely accepted that cirrhosis from recurrent HCV occurs in up to 30% of patients within five years of transplantation.

8 Jun 2011

Intercell, Merck terminate V710 Phase II/III trial against S. aureus infection

Merck, known as MSD outside the United States and Canada, and Intercell AG (VSE: ICLL) today announced that following a detailed analysis of the data from the Phase II/III clinical trial evaluating V710, an investigational vaccine for the prevention of Staphylococcus aureus (S. aureus) infection, the independent Data Monitoring Committee (DMC) has unanimously recommended termination of the study.

8 Jun 2011

Pharmasset expands PSI-7977 clinical trial for treatment of chronic hepatitis C

Pharmasset, Inc. announced today the addition of three treatment cohorts to the ELECTRON trial of PSI-7977, a nucleotide analog polymerase inhibitor, for the treatment of chronic hepatitis C (HCV).

8 Jun 2011

Hepatitis C patients with chronic liver disease may benefit from drinking coffee during treatment

Advanced hepatitis C patients with chronic liver disease may benefit from drinking coffee during treatment, according to a new study in Gastroenterology, the official journal of the American Gastroenterological Association (AGA) Institute.

8 Jun 2011

NanoViricides' anti-influenza drug development studies to be presented at TechConnect World 2011

NanoViricides, Inc. announced today that it has been invited to present its anti-influenza drug development studies at the TechConnect World 2011 Conferences and Expo.

7 Jun 2011

Viewpoints: Reps. on Medicare politics, policies, community pharmacies; Reflections on AIDS

The [Ryan] privatization proposal overlooks the fact that when it comes to rising health costs, Medicare is part of the solution, not the problem. ... Together with health care reform, Medicare can be the driver of innovation due to its sheer market share.

6 Jun 2011

Denali, Can-Fite sign agreement to conclude ophthalmology spinoff

Can-Fite BioPharma Ltd, a biotechnology company developing small molecule drugs for the treatment of inflammatory, ophthalmic, and liver diseases, traded on the Tel Aviv Stock Exchange, signed today an agreement to spin off its ophthalmic indications to a US based public company, Denali Concrete Management Inc.

6 Jun 2011

Bharat Biotech announces the pricing for ROTAVAC vaccine

Bharat Biotech today announced the price of ROTAVAC India’s first indigenously developed Rotavirus Vaccine. The vaccine will be sold to global public markets, Governments worldwide including UN procurement agencies at a price of US $ 1.0. Bharat Biotech hopes its new vaccine will help prevent part of the ~ 500,000 child deaths each year caused due to rotavirus diarrhea and improve access to better, affordable rotavirus vaccines.

6 Jun 2011

GAVI welcomes lower pentavalent vaccine price

In the lead up to its first pledging conference on June 13, the GAVI Alliance announced today it has achieved commitments from two emerging market vaccine manufacturers to lower prices for the life-saving pentavalent vaccine, which protects against five deadly diseases. Developed country manufacturers have also offered price reductions on rotavirus and human papillomavirus, or HPV, vaccines.

5 Jun 2011

Primary care providers treat hepatitis C patients effectively through Project ECHO model

Under a completely new way of providing health care, primary care clinicians in remote villages, prisons and poor urban neighborhoods who were trained to treat patients with hepatitis C achieved excellent results identical to those of specialists at a university medical center.

4 Jun 2011

UCLA pediatric investigators earn top accolades at TTCF Faculty Presentation Awards

A new therapy for type 1 diabetes? A promising treatment for deadly viruses? Does a common treatment for children with severe infection actually cause more harm than good? These are important questions being investigated by pediatric researchers at Mattel Children's Hospital UCLA.

4 Jun 2011

Technology, expert training and real-time feedback improves Hepatitis C outcomes

Widely-available technology, expert training and real-time feedback helped ensure that patients treated for Hepatitis C in local communities did as well as patients treated at a university-based medical center, results of a new study funded by HHS' Agency for Healthcare Research and Quality show. The study is published in the June 2 online issue of the New England Journal of Medicine and in the June 9 print edition.

3 Jun 2011

Hepatitis C News and Research

Latest Hepatitis C News and Research

Alios, Vertex sign worldwide license agreement to develop new hepatitis C combination medicines

MinuteClinic, OhioHealth enter affiliation to enhance high quality care services

Vertex VX-770 Phase 3 STRIVE study for cystic fibrosis demonstrates improvements in lung function

Mortality from all causes higher among hepatitis C-infected patients, study finds

NIAID awards Biota $2.9M grant for development of lead candidate for C. difficile

Vertex announces interim results from VX-770 and VX-809 Phase 2 study on cystic fibrosis

Cancer professionals urge world leaders to attend U.N. meeting on NCDs

Rockefeller, Scripps Research develop first genetically humanized mouse model for hepatitis C

Hepatitis C virus (HCV)-associated liver disease after liver transplantation

Intercell, Merck terminate V710 Phase II/III trial against S. aureus infection

Pharmasset expands PSI-7977 clinical trial for treatment of chronic hepatitis C

Hepatitis C patients with chronic liver disease may benefit from drinking coffee during treatment

NanoViricides' anti-influenza drug development studies to be presented at TechConnect World 2011

Viewpoints: Reps. on Medicare politics, policies, community pharmacies; Reflections on AIDS

Denali, Can-Fite sign agreement to conclude ophthalmology spinoff

Bharat Biotech announces the pricing for ROTAVAC vaccine

GAVI welcomes lower pentavalent vaccine price

Primary care providers treat hepatitis C patients effectively through Project ECHO model

UCLA pediatric investigators earn top accolades at TTCF Faculty Presentation Awards

Technology, expert training and real-time feedback improves Hepatitis C outcomes

The Proteoform Puzzle: Unlocking the Next Frontier

Synthetic Biology and the Pursuit of Living Diagnostics

Modular, Scalable, Intelligent: How n6 Is Rethinking NGS Library Prep

Hepatitis C News and Research

Latest Hepatitis C News and Research

The Proteoform Puzzle: Unlocking the Next Frontier

Synthetic Biology and the Pursuit of Living Diagnostics

Modular, Scalable, Intelligent: How n6 Is Rethinking NGS Library Prep

Newsletters you may be interested in